|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07K2317/76 | (2013.01) | ||
| A61K 31/542 | (2006.01) | ||
| A61K 31/542 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| C07K 16/2827 | (2013.01) | ||
| A61K 31/55 | (2013.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61K 39/3955 | (2013.01) |
| (11) | Number of the document | 3458091 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17726073.4 |
| Date of filing the European patent application | 2017-05-16 | |
| (97) | Date of publication of the European application | 2019-03-27 |
| (45) | Date of publication and mention of the grant of the patent | 2021-11-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/032790 |
| Date | 2017-05-16 |
| (87) | Number | WO 2017/200969 |
| Date | 2017-11-23 |
| (30) | Number | Date | Country code |
| 201662339363 P | 2016-05-20 | US |
| (72) |
BENDER, Mark Harrath , US
GAO, Hong , US
PATEL, Bharvin Kumar , US
|
| (73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS |
| COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS |